ArticleScience advances2019
Synthetic self-assembling ADDomer platform for highly efficient vaccination by genetically encoded multiepitope display.
Article in Science advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Engineering the ADDomer Nanoparticle Vaccine Scaffold for Improved Assembly and Enhanced Stability.ACS synthetic biology · 2026Article
- Streamlined purification of ADDomer nanoparticles for scalable biomanufacturing.Journal of biological engineering · 2025Article
- Pre-Existing Anti-Vector Immunity to Adenovirus-Inspired VLP Vaccines Shows an Adjuvant-Dependent Antagonism.Vaccines · 2025Article
- Foot-and-mouth disease virus-like particle vaccine incorporating dominant T and B cell epitopes: enhanced immune response in piglets with CD154 molecules.Frontiers in veterinary science · 2025Article
- Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections.Veterinary research · 2024Review
- Engineering the ADDobody protein scaffold for generation of high-avidity ADDomer super-binders.Structure (London, England : 1993) · 2024Article
- A modular approach to enhancing cell membrane-coated nanoparticle functionality using genetic engineering.Nature nanotechnology · 2024Article
- Review
- ADDovenom: Thermostable Protein-Based ADDomer Nanoparticles as New Therapeutics for Snakebite Envenoming.Toxins · 2023Article
- Article
- Review
- Stimulation of the immune system by a tumor antigen-bearing adenovirus-inspired VLP allows control of melanoma growth.Molecular therapy. Methods & clinical development · 2023Article
- Virus-like particle vaccines with epitopes from porcine epidemic virus and transmissible gastroenteritis virus incorporated into self-assembling ADDomer platform provide clinical immune responses in piglets.Frontiers in immunology · 2023Article
- Adenovirus-Inspired Virus-Like-Particles Displaying Melanoma Tumor Antigen Specifically Target Human DC Subsets and Trigger Antigen-Specific Immune Responses.Biomedicines · 2022Article
- Using Self-Assembling ADDomer Platform to Display B and T Epitopes of Type O Foot-and-Mouth Disease Virus.Viruses · 2022Article
- Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- On the use of adenovirus dodecahedron as a carrier for glycoconjugate vaccines.Glycoconjugate journal · 2021Article
- Nanocarrier vaccines for SARS-CoV-2.Advanced drug delivery reviews · 2021Article
- VLP-factory™ and ADDomerCurrent protocols · 2021Article
- The Adenovirus Dodecahedron: Beyond the Platonic Story.Viruses · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Self-assembling virus-like particles represent highly attractive tools for developing next-generation vaccines and protein therapeutics. We created ADDomer, an adenovirus-derived multimeric protein-based self-assembling nanoparticle scaffold engineered to facilitate plug-and-play display of multiple immunogenic epitopes from pathogens. We used cryo-electron microscopy at near-atomic resolution and implemented novel, cost-effective, high-performance cloud computing to reveal architectural features in unprecedented detail. We analyzed ADDomer interaction with components of the immune system and developed a promising first-in-kind ADDomer-based vaccine candidate to combat emerging Chikungunya infectious disease, exemplifying the potential of our approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.